PT  - JOURNAL ARTICLE
AU  - Sonja C M Bloch
AU  - Louise J Jackson
AU  - Emma Frew
AU  - Jonathan D C Ross
TI  - Assessing the costs and outcomes of control programmes for sexually transmitted infections: a systematic review of economic evaluations
AID  - 10.1136/sextrans-2020-054873
DP  - 2021 Mar 02
TA  - Sexually Transmitted Infections
PG  - sextrans-2020-054873
4099  - http://sti.bmj.com/content/early/2021/03/02/sextrans-2020-054873.short
4100  - http://sti.bmj.com/content/early/2021/03/02/sextrans-2020-054873.full
AB  - Objective To identify economic evaluations of interventions to control STIs and HIV targeting young people, and to assess how costs and outcomes are measured in these studies.Design Systematic review.Data sources Seven databases were searched (Medline (Ovid), EMBASE (Ovid), Web of Science, PsycINFO, NHS Economic Evaluation Database, NHS Health Technology Assessment and Database of Abstracts of Reviews of Effects) from January 1999 to April 2019. Key search terms were STIs (chlamydia, gonorrhoea, syphilis) and HIV, cost benefit, cost utility, economic evaluation, public health, screening, testing and control.Review methods Studies were included that measured costs and outcomes to inform an economic evaluation of any programme to control STIs and HIV targeting individuals predominantly below 30 years of age at risk of, or affected by, one or multiple STIs and/or HIV in Organisation for Economic Co-operation and Development countries. Data were extracted and tabulated and included study results and characteristics of economic evaluations. Study quality was assessed using the Philips and BMJ checklists. Results were synthesised narratively.Results 9530 records were screened and categorised. Of these, 31 were included for data extraction and critical appraisal. The majority of studies assessed the cost-effectiveness or cost-utility of screening interventions for chlamydia from a provider perspective. The main outcome measures were major outcomes averted and quality-adjusted life years. Studies evaluated direct medical costs, for example, programme costs and 11 included indirect costs, such as productivity losses. The study designs were predominantly model-based with significant heterogeneity between the models.Discussion/Conclusion None of the economic evaluations encompassed aspects of equity or context, which are highly relevant to sexual health decision-makers. The review demonstrated heterogeneity in approaches to evaluate costs and outcomes for STI/HIV control programmes. The low quality of available studies along with the limited focus, that is, almost all studies relate to chlamydia, highlight the need for high-quality economic evaluations to inform the commissioning of sexual health services.